Have a personal or library account? Click to login
Cyclodextrin based nanosponges for pharmaceutical use: A review Cover

Cyclodextrin based nanosponges for pharmaceutical use: A review

Open Access
|Oct 2013

References

  1. 1. L. Guo, G. Gao, X. Liu and F. Liu, Preparation and characterization of TiO2 nanosponge, Mater. Chem. Phys. 111 (2008) 322-325; DOI: 10.1186/1556-276X-6-551.10.1186/1556-276X-6-551
  2. 2. D. Farrell, S. Limaye and S. Subramanian, Silicon Nanosponge Particles, U.S. Pat 0,251,561A1, 9 Nov 2006.
  3. 3. V. Dakankov, M. Llyin, M. Tsyurupa, G. Timofeeva and L. Dubronina, From a dissolved polystyrene coil to intramolecularly hyper cross linked nanosponges, Macromolecules 29 (1998) 8398-8403; DOI: 10.1021/ma951673i.10.1021/ma951673i
  4. 4. S. Swaminathan, L. Pastero, L. Serpe, F. Trotta, P. Vavia, D. Aquilano, M. Trotta, G. Zara and R. Cavalli, Cyclodextrin-based nanosponges encapsulating camptothecin: Physicochemical characterization, stability and cytotoxicity, Eur. J. Pharm. Biopharm. 74 (2010) 193-201; DOI: 10.1016/ j.ejpb.2009.11.003.10.1016/j.ejpb.2009.11.003
  5. 5. F. Melani, P. Mura, M. Adamo, F. Maestrelli, P. Gratteri and C. Bonaccini, New docking CFF91 parameters specific for cyclodextrin inclusion complexes, Chem. Phys. Lett. 370 (2003) 280-292; DOI: 10.1016/S0009-2614(03)00126-X.10.1016/S0009-2614(03)00126-X
  6. 6. P. Couvreur and C. Vauthier, Nanotechnology: intelligent design to treat complex disease, Pharm. Res. 23 (2006) 1417-1450; DOI: 10.1007/s11095-006-0284-8.10.1007/s11095-006-0284-8
  7. 7. C. Zhang, N. Awasthi, M. A. Schwarz, S. Hinz and R. E. Schwarz, Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer, PLoS One. 8 (2013) e58037; DOI: 10.1371/journal.pone.0058037.10.1371/journal.pone.0058037
  8. 8. Y. Fukumori and H. Ichikawa, Nanoparticles for cancer therapy and diagnosis, Adv. PowderTechnol. 17 (2006) 1-28; DOI: 10.1163/156855206775123494.10.1163/156855206775123494
  9. 9. M. Morishita and N. Peppas, Is the oral route possible for peptide and protein drug delivery, Drug Discov. Today 11 (2006) 905-910; DOI: 10.1007/s11095-006-0284-8.10.1007/s11095-006-0284-8
  10. 10. H. Cohen, R. Levy, J. Gao, I. Fishbein, V. Kousaev, S. Sosnowski, S. Slomkowski and G. Golomb, Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles, Gene Ther. 7 (2000) 1896-1905; DOI: 10.1038/sj.gt.3301318.10.1038/sj.gt.3301318
  11. 11. L. Grislain, P. Couvreur, V. Lenaerts, M. Roland, D. Deprez-Decampeneere and P. Speiser, Pharmacokinetics and distribution of a biodegradable drug-carrier, Int. J. Pharm. 15 (1983) 335-345; DOI: 10.1016/0378-5173(83)90166-7.10.1016/0378-5173(83)90166-7
  12. 12. L. Illum, S. S. Davis, C. G. Wilson, N. W. Thomas, M. Frier and J. G. Hardy, Blood clearance and organ deposition of intravenously administered colloidal particles, The effects of particle size, nature and shape, Int. J. Pharm. 12 (1982) 135-146; DOI: 10.1016/0378-5173(82)90113-2.10.1016/0378-5173(82)90113-2
  13. 13. P. Couvreur, B. Kante, V. Lenaerts, V. Scailteur, M. Roland and P. Speiser, Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles, J. Pharm. Sci. 69 (1980) 199-202; DOI: 10.1002/jps.2600690222.10.1002/jps.26006902227359324
  14. 14. J. Kreuter, Nanoparticles, in Encyclopedia of Pharmaceutical Technology (Ed. J. Swarbrick and J. C. Boylan), Marcel Dekker In., New York 1994, pp.165-190.
  15. 15. J. Xing, D. Zhang and T. Tan, Studies on the oridonin-loaded poly(D,L-lactic acid) nanoparticles in vitro and in vivo, Int. J. Biol. Macromol. 40 (2007) 153-158; DOI: 10.1016/j.ijbiomac.2006. 07.001.
  16. 16. E. Garcia-Garcia, K. Andrieux, S. Gil and P. Couvreur, Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain, Int. J. Pharm. 298 (2005) 274-292; DOI: 10.1016/j.ijpharm.2005.03.031.10.1016/j.ijpharm.2005.03.03115896933
  17. 17. S. Subramanian, A. Singireddy, K. Krishnamoorthy and M. Rajappan, Nanosponges: A Novel Class of Drug Delivery System - Review, J. Pharm. Pharmac. Sci. 15 (2012) 103-111.
  18. 18. A. Nokhodchi, M. Jelvehgari, M. Reza Siahi and M. Reza Mozafar, Factors affecting the morphology of benzoyl peroxide microsponges, Micron 38 (2007) 834-840, DOI: 10.1016/j.micron. 2007.06.012.
  19. 19. F. Trotta and R. Cavalli, Characterization and application of new hyper-cross-linked cyclodextrins, Compos. Interfaces 16 (2009) 39-48, DOI: 10.1163/156855408X379388.10.1163/156855408X379388
  20. 20. F. Trotta, R. Cavalli, V. Tumiatti, O. Zerbinati, C. Roggero and R. Vallero, Ultrasound AssistedSynthesis of Cyclodextrin Based Nanosponges, EP Pat 1786841A1, 23May, 2007.
  21. 21. S. Eki, T. Lei, L. Jingquan, J. Zhongfan, B. Cyrille and P. D. Thomas, Biodegradable star polymers functionalized with b-cyclodextrin inclusion complexes, Biomacromolecules, 10 (2009) 2699-2707; DOI: 10.1021/bm900646g.10.1021/bm900646g19663421
  22. 22. S. Swaminathan, R. Cavalli, F. Trotta, P. Ferruti, E. Ranucci, I. Gerges, A. Manfredi, D. Marinotto and P. Vavia, In vitro release modulation and conformational stabilization of a model protein using swellable polyamidoamine nanosponges of b-cyclodextrin, J. Incl. Phenom. Macrocycl. Chem. 68 (2010) 183-191; DOI: 10.1007/s10847-010-9765-9.10.1007/s10847-010-9765-9
  23. 23. A. Vyas, S. Saraf and S. Saraf, Cyclodextrin based novel drug delivery systems, J. Incl. Phenom. Macrocycl. Chem. 62 (2008) 23-42; DOI: 10.1007/s10847-008-9456-y.10.1007/s10847-008-9456-y
  24. 24. T. Girek and W. Ciesielski, Polymerization of b-cyclodextrin with maleic anhydride along with thermogravimetric study of polymers, J. Incl. Phenom. Macrocycl. Chem. (2010) 1-7; DOI: 10. 1007/s10847-010-9778-4.
  25. 25. D. Li and M. Ma, Nanosponges: From inclusion chemistry to water purifying technology, Chem.\ Sci. Technol. (1999) 26-28.
  26. 26. C. Rajeswari, A. Alka, A. Javed and R. Khar, Cyclodextrins in drug delivery: an update review, AAPS PharmSciTech. 6 (2005) E329-E357; DOI: 10.1208/pt060243.10.1208/pt060243275054616353992
  27. 27. A. Modi and P. Tayade, Comparative solubility enhancement profile of valdecoxib with different solubilization approaches, Ind. J. Pharm. Sci. 69 (2007) 427-430; DOI: 10.4103/0250-474X. 33156.
  28. 28. R. Cavalli, F. Trotta and W. Tumiatti, Cyclodextrin-based nanosponges for drug delivery, J. Incl. Phenom. Macrocycl. Chem. 56 (2006) 209-213; DOI: 10.1007/s10847-006-9085-2.10.1007/s10847-006-9085-2
  29. 29. F. Trotta, V. Tumiatti, R. Cavalli, C. Roggero, B. Mognetti and G. Berta, Cyclodextrin-based Nanospongesas a Vehicle for Antitumoral Drugs, WO 2009/003656 A1; 2009.
  30. 30. F. Trotta and T. Wander, Cross-linked Polymers Based on Cyclodextrins for Removing PollutingAgents, WO 2003/085002, US20050154198 A1, 14 July. 2005.
  31. 31. S. Swaminathan, P. Vavia, F. Trotta and S. Torne, Formulation of beta-cyclodextrin based nanosponges of Itraconazole, J. Incl. Phenom. Macrocycl. Chem. 57 (2007) 89-94; DOI: 10.1007/s10847-006-9216-9.10.1007/s10847-006-9216-9
  32. 32. A. Mele, F. Castiglione, L. Malpezzi, F. Ganazzoli, G. Raffaini, F. Trotta, B. Rossi, A. Fontana and G. Giunchi, HR MAS NMR, powder XRD and Raman spectroscopy study of inclusion phenomena in b-CD nanosponges, J. Incl. Phenom. Macrocycl. Chem. 69 (2011) 403-409; DOI: 10.1007/ s10847-010-9772-x.10.1007/s10847-010-9772-x
  33. 33. S. Swaminathan, P. Vavia, F. Trotta, R. Cavalli, P. Ferruti, E. Ranucci and I. Gerges, Release modulation and conformational stabilization of a model protein by use of swellable nanosponges of b-cyclodextrin, First European Cyclodextrin Conference, Aalborg, Denmark 2009.
  34. 34. S. Torne, K. Ansari, P. Vavia, F. Trotta and R. Cavalli, Enhanced oral bioavailability after administration of paclitaxel-loaded nanosponges, Drug Deliv. 17 (2010) 419-425; DOI: 10.3109/ 10717541003777233.10.3109/1071754100377723320429848
  35. 35. K. Ansari, P. Vavia, F. Trotta and R. Cavalli, Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study, AAPS PharmSciTech, 12 (2011) 279-286; DOI: 10.1208/s12249-011-9584-3.10.1208/s12249-011-9584-3306634021240574
  36. 36. E. Patel and R. Oswal, Nanosponge and micro sponges: a novel drug delivery system, Int. J. Res. Pharm. Chem. 2 (2012) 237-244.
  37. 37. T. Loftsson and M. Brewster, Pharmaceutical applications of cyclodextrins: drug solubilization and stabilization, J. Pharm. Pharmacol. 85 (1996) 1017-1025; DOI: 10.1021/js950534b.10.1021/js950534b8897265
  38. 38. A. Radi and S. Eissa, Electrochemical study of indapamide and its complexation with b-cyclodextrin, J. Incl. Phenom. Macrocycl. Chem. 71 (2011) 95-102; DOI: 10.1007/s10847-010.9906-1.10.1007/s10847-010-9906-1
  39. 39. H. Bricout, F. Hapiot, A. Ponchel, E. Monflier and S. Tilloy, Chemically modified cyclodextrins: an attractive class of supramolecular hosts for the development of aqueous biphasic catalytic processes, Sustainability 1 (2009) 924-945; DOI: 10.3390/su1040924.10.3390/su1040924
  40. 40. H. Dodziuk, Molecules with Holes - Cyclodextrins, in Cyclodextrins and Their Complexes (Ed. H. Dodziuk), Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim 2006, pp. 1-30.10.1002/3527608982.ch1
  41. 41. D. Li and M. Ma, Nanosponges for water purification, Clean Prod. Process. 2 (2000) 112-16; DOI: 10.1007/s100980000061.10.1007/s100980000061
  42. 42. E. Bilensoy and A. Atilla, Cyclodextrin-based Nanomaterials in Pharmaceutical Field, in PharmaceuticalSciences Encyclopedia: Drug Discovery, Development, and Manufacturing, John Wiley & Sons Inc. Publishers 2010; DOI: 10.1002/9780470259818.ch31.10.1002/9780470571224.pse370
  43. 43. R. Lala, A. Thorat and C. Gargote, Current trends in b-cyclodextrin based drug delivery systems, Int. J. Res. Ayur. Pharm, 2 (2011) 1520-1526.
  44. 44. B. Mamba, R. Krause, T. Malefetse and S. Sithhole, Cyclodextrin nanosponges in the removal of organic matter to produce water for power generation, Water SA, 34 (2008) 657-660.10.4314/wsa.v34i5.180666
  45. 45. B. Mamba, R. Krause, T. Malefetse, S. Mhlanga, S. Sithhole, K. Salipira and E. Nxumalo, Removal of geosmin and 2-methylisoborneol (2-MIB) in water from Zuikerbosch water treatment plant (Rand Water) using b-cyclodextrin polyurethane, Water SA, 32 (2007) 223-228.
  46. 46. S. Tang, L. Kong, J. Ou, Y. Liu, X. Li and H. Zou, Application of cross-linked b-cyclodextrin polymer for adsorption of aromatic amino acid, J. Mol. Recogn. Macrocyclic Chem. 19 (2006) 39-48; DOI: 10.1002/jmr.756.10.1002/jmr.75616265676
  47. 47. F. Trotta, R. Cavalli, S. Swaminathan, C. Sarzanini and P. Vavia, Novel functionalized nanosponges: synthesis, characterization. Safety assessment, cytotoxicity testing and interaction studies. Proceedings of the 14th International Cyclodextrin Symposium, Kyoto 2008, pp. 338-342.
  48. 48. G. Yurtdas, M. Demirel and L. Genc, Inclusion complexes of fluconazole with b-cyclodextrin: physicochemical characterization and in vitro evaluation of its formulation, J. Incl. Phenom. Macrocycl. Chem. 70 (2011) 429-435; DOI: 10.1007/s10847-010-9908-z.10.1007/s10847-010-9908-z
  49. 49. A. Rasheed, Cyclodextrins as drug carrier molecule: a review, Sci. Pharmac. 76 (2008) 567-598; DOI: 10.3797/scipharm.0808-05.10.3797/scipharm.0808-05
  50. 50. P. Sinko, Martin’s Physical Pharmacy and Pharmaceutical Sciences, 5th ed., Lippincott Williams & Williams Publishers, Philadelphia 2006, p.466.
  51. 51. T. Govender, S. Stolnik, M. Garnett, L. Illum and S. Davis, PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug, J. Control. Release 57 (1999) 171-185; DOI: 10.1016/S0168-3659(98)00116-3.10.1016/S0168-3659(98)00116-3
  52. 52. S. Galindo-Rodriguez, E. Allémann, H. Fessi and E. Doelker, Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion and nanoprecipitation methods, Pharm. Res. 21 (2004) 1428-1439; DOI: 10.1023/B:PHAM.0000036917.75634.be.10.1023/B:PHAM.0000036917.75634.be
  53. 53. M. Leroueil-Le Verger, L. Fluckiger, Y. Kim, M. Hoffman and P. Maincent, Preparation and characterization of nanoparticles containing an antihypertensive agent, Eur. J. Pharm. Biopharm. 46 (1998) 137-143; DOI: 10.1016/S0939-6411(98)00015-0.10.1016/S0939-6411(98)00015-0
  54. 54. N. Santos-Magalhães, H. Fessi, F. Puisieux, S. Benita and M. Seiller, An in-vitro release kinetic examination and comparative evaluation between submicron emulsion and polylactic acid nanocapsules of clofibride, J. Microencapsul. 12 (1995) 195-205; DOI: 10.3109/02652049509015290.10.3109/02652049509015290
  55. 55. A. Layre, R. Gref, J. Richard, D. Requier, H. Chacun, M. Appel, A. Domb and P. Couvreur, Nanoencapsulation of a crystalline drug, Int. J. Pharm. 298 (2005) 323-327; DOI: 10.1016/j. ijpharm.2005.02.039.10.1016/j.ijpharm.2005.02.039
  56. 56. D. Lemoine, C. Francois, F. Kedzierewicz, V. Preat, M. Hoffman and P. Maincent, Stability study of nanoparticles of poly(b-caprolactone), poly(D,L-lactide) and poly(D,L-lactideco-glycolide), Biomaterials 17 (1996) 2191-2197. DOI: 10.1016/0142-9612(96)00049-X.10.1016/0142-9612(96)00049-X
  57. 57. Y. Jeong, Y. Shim, C. Kim, G. Lim, K. Choi and C. Yoon, Effect of cryoprotectants on the reconstitution properties of surfactant-free nanoparticles of poly (D,L-lactide-co-glycolide), J. Microencapsul.22 (2005) 593-601; DOI: 10.1080/02652040500162659.10.1080/02652040500162659
  58. 58. H. Redhead, S. Davis and L. Illum, Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation, J. Control. Release, 70 (2001) 353-363; DOI: 10.1016/S0168-3659(00)00367-9.10.1016/S0168-3659(00)00367-9
  59. 59. M. Bivas-Benita, S. Romeijn, H. Junginger and G. Borchard, PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium, Eur. J. Pharm. Biopharm. 58 (2004) 1-6; DOI: 10.1016/j.ejpb. 2004.03.008.
  60. 60. R. Pecora, Dynamic light scattering measurement of nanometer particles in liquids, J. NanoparticleRes. 2 (2000) 123-131; DOI: 10.1023/A:1010067107182.10.1023/A:1010067107182
  61. 61. M. Santander-Ortega, A. Jódar-Reyes, N. Csabac, D. Bastos-González and J. Ortega-Vinuesa, Colloidal stability of Pluronic F68-coated PLGA nanoparticles: a variety of stabilisation mechanisms, J. Colloid. Interf. Sci. 302 (2006) 522-529; DOI: 10.1016/j.jcis.2006.07.031.10.1016/j.jcis.2006.07.031
  62. 62. Y. Ishikawa, Y. Katoh and H. Ohshima, Colloidal stability of aqueous polymeric dispersions: effect of pH and salt concentration, Colloid Surf. B 42 (2005) 53-58; DOI: 10.1016/j.colsurfb.2005. 01.006.
  63. 63. J. Shar, T. Obey and T. Cosgrove, Adsorption studies of polyether’s- Part1: Adsorption onto hydrophobic surfaces, Colloid Surf A: Physicochemical and Engineering Aspects 136 (1998) 21-33, DOI: 10.1016/S0927-7757(97)00182-9.10.1016/S0927-7757(97)00182-9
  64. 64. E. Leo, B. Brina, F. Forni and M. Vandelli, In vitro evaluation of PLA nanoparticles containing a lipophilic drug in water-soluble or insoluble form, Int. J. Pharm. 278 (2004) 133-141, DOI: 10. 1016/j.ijpharm.2004.03.002.10.1016/j.ijpharm.2004.03.002
  65. 65. U. Bilati, E. Allemann and E. Doelker, Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles, Eur. J. Pharm. Sci. 24 (2005) 67-75; DOI: 10.1016/j.ejps.2004.09.011.10.1016/j.ejps.2004.09.011
  66. 66. M. Bivas-Benita, S. Romeijn, H. Junginger and G. Borchard, PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium, Eur. J. Pharm. Biopharm. 58 (2004) 1-6; DOI: 10.1016/j.ejpb. 2004.03.008.
  67. 67. H. Fessi, F. Puisieux, J. Devissaguet, N. Ammoury and S. Benita, Nanocapsule formation by interfacial polymer deposition following solvent displacement, Int. J. Pharm. 55 (1989) R1-R4; DOI: 10.1016/0378-5173(89)90281-0.10.1016/0378-5173(89)90281-0
  68. 68. M. Chorny, I. Fishbein, H. D. Danenberg and G. Golomb, Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics, J. Control. Release 83 (2002) 389-400; DOI: 10.1016/S0168-3659(02)00211-0.10.1016/S0168-3659(02)00211-0
  69. 69. V. Mosqueira, P. Legrand, H. Pinto-Alphandary, F. Puisieux and G. Barratt, Poly (D,L-lactide) nanocapsules prepared by a solvent displacement process: influence of the composition on physicochemical and structural properties, J. Pharm. Sci. 89 (2000) 614-626; DOI: 10.1002/(SICI) 1520-6017(200005)89:5<614::AID-JPS7>3.0.CO;2-7.
  70. 70. J. Ren, H. Hong, J. Song and T. Ren, Particle size and distribution of biodegradable poly-D,L- -lactide-co-poly(ethylene glycol) block polymer nanoparticles prepared by nanoprecipitation, J. Appl. Polym. Sci. 98 (2005) 1884-1890; DOI: 10.1002/app.22070.10.1002/app.22070
  71. 71. M. Teixeira, M. Alonso, M. Pinto and C. Barbosa, Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3methoxyxanthone, Eur. J. Pharm. Biopharm. 59 (2005) 491-500; DOI: 10.1016/j.ejpb.2004.09.002.10.1016/j.ejpb.2004.09.00215760730
  72. 72. M. Tobìo, R. Gref, A. Sanchez, R. Langer and M. Alonso, Stealth PLA-PEG nanoparticles as protein carriers for nasal administration, Pharm. Res. 15 (1998) 276-279; DOI: 10.1023/A:1011922 819926.
  73. 73. H. Brittain, D. Bogdanowich, J. DeVincentis, G. Lewen and A.Newman, Physical characterization of pharmaceutical solids, Pharm. Res. 8 (1991) 963-973. DOI: 10.1023/A:1015888520352.10.1023/A:1015888520352
  74. 74. M. Hombreiro-Perez, J. Siepmann, C. Zinutti, A. Lamprecht, N. Ubrich, M. Hoffman, R. Bodmeier and P. Maincent, Non-degradable microparticles containing a hydrophilic and/or a lipophilic drug: preparation, characterization and drug release modeling, J. Control. Release 88 (2003) 413-428; DOI: 10.1016/S0168-3659(03)00030-0.10.1016/S0168-3659(03)00030-0
  75. 75. M. Guyot and F. Fawaz, Nifedipine loaded-polymeric microspheres: preparation and physical characteristics, Int. J. Pharm. 175 (1998) 61-74; DOI: 10.1016/S0378-5173(98)00253-1.10.1016/S0378-5173(98)00253-1
  76. 76. Y. Jeong, Y. Shim, K. Song, Y. Park, H. Ryu and J. Nah, Testosterone encapsulated surfactant-free nanoparticles of poly(D,L-lactide-co-glycolide): preparation and release behavior, Bull. KoreanChem. Soc. 23 (2002) 1579-1584.
  77. 77. R. Suryanarayanan, X-Ray Powder Diffractometry, in Physical Characterization of Pharmaceutical Solids, Vol. 70 (Ed. H. G. Brittain), Marcel Dekker Inc., New York 1995, pp.187-221.10.1201/b14204-8
  78. 78. J. Alongi, M. Skovi, A. Frache and F. Trotta, Novel flame retardants containing cyclodextrin nanosponges and phosphorus compounds to enhance EVA combustion properties, Polym. Degrad. Stabil. 95 (2010) 2093-2100; DOI: 10.1016/j.polymdegradstab.2010.06.030.10.1016/j.polymdegradstab.2010.06.030
  79. 79. G. Gilardi, F. Trotta, R. Cavalli, P. Ferruti, E. Ranucci, G. Di Nardo, C. Roggero and V. Tumiatti, Cyclodextrin Nanosponges as Carrier for Biocatalysts, and in the Delivery and Release of Enzymes, Proteins,Vaccines and Antibodies, WO2009149883 A1, 17 Dec.2009.
  80. 80. S. Renuka, B. W. Roderick and P. Kamla, Evaluation of the kinetics and mechanism of drug release from Econazole Nitrate nanosponge loaded carbopol hydrogel, Ind. J. Pharm. Edu. Res. 45 (2011) 25-31.
  81. 81. S. Renuka and P. Kamla, Polymeric nanosponges as an alternative carrier for improved retention of econazole nitrate onto the skin through topical hydrogel formulation, Pharm. Dev. Technol.16 (2011) 367-376; DOI: 10.3109/10837451003739289.10.3109/1083745100373928920367024
  82. 82. S. Baboota, R. Khanna, S. Agarwal, J. Ali and A. Ahuja, Cyclodextrins in Drug Delivery Systems: An update, Available from Pharma. info. net., 2003, accessed on 13/01/2011.
  83. 83. V. N. Wong, G. Fernando, A. R. Wagner, J. Zhang, G. R. Kinsel, S. Zauscher and D. J. Dyer, Separation of peptides with polyionic nanosponges for MALDIMS analysis, Langmuir 25 (2009) 1459-1465; DOI: 10.1021/la802723r.10.1021/la802723r271679619123797
  84. 84. A. Jenny, P. Merima, F. Alberto and T. Francesco, Role of b-cyclodextrin nanosponges in polypropylene photooxidation, Carbohyd. Polym. 86 (2011) 127-135; DOI: 10.1016/j.carbpol.2011.04. 022.
  85. 85. K. William, S. Benjamin and H. Eva, Synthesis and Characterization of Nanosponges for Drug Deliveryand Cancer Treatment, www.Vanderbilt.edu, accessed on 20.12.2011.
  86. 86. L. Wenting, Y. Cheng, N. Masaki, F. Gaku, M. Tadashi, M. Andrea, C. Franca, C. Fabrizio, T. Francesco and I. Yoshihisa, Cyclodextrin nanosponge-sensitized enantiodifferentiating photoisomerization of cyclooctene and 1,3-cyclooctadiene, Beilstein J. Org. Chem. 8 (2012) 1305-1311; DOI: 10.3762/bjoc.8.149. 10.3762/bjoc.8.149345875423019464
DOI: https://doi.org/10.2478/acph-2013-0021 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Language: English
Page range: 335 - 358
Published on: Oct 22, 2013
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:

© 2013 Gursalkar Tejashri, Bajaj Amrita, Jain Darshana, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons License.